Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Møller DS, Nielsen TB, Brink C, Hoffmann L, Lutz CM, Drøgemüller Lund M, Hansen O, Schytte T, Khalil AA, Knap MM, Nyhus CH, Ottosson W, Sibolt P, Borissova S, Josipovic M, Persson G, Appelt AL.
Møller DS, et al. Among authors: nielsen tb.
Radiother Oncol. 2017 Aug;124(2):311-317. doi: 10.1016/j.radonc.2017.06.022. Epub 2017 Jul 5.
Radiother Oncol. 2017.
PMID: 28688525
Free article.
Clinical Trial.